August 2021

With Covid-19 vaccine programmes racing full steam ahead, we turn our attention to another vaccine debate, this time surrounding chickenpox. Although a safe and effective vaccine against the condition has been available since 1988 and is a common part of routine childhood vaccinations in the US, the UK Government has opted to forgo the treatment. But why is this? In the next issue of Pharma Technology Focus, we find out.

Also, we unpack the research behind Swiss pharma firm Ferring Pharmaceuticals’ potential microbiome breakthrough, explore the history of ALS treatments and examine the potential consequences facing manufacturers if a proposed vaccine patent waiver becomes a reality.

Plus, we learn more about the fight to combat black fungus in India as manufacturers in the country race to develop anti-fungal drugs amid growing case numbers, find out how light-sensing algae proteins are being used in a standout therapy for sight impairment and get the latest insight and analysis from GlobalData.

EDITORIAL

Editor | Eloise McLennan

Writers | Abi Millar, Chloe Kent, Natalie Healey, Darcy Jimenez, Eric Caugant, Judi Sills
Magazine Designer | Marzia Del Gaone

Graphic Designers | Anett Arc, Ashley McPherson, Tyrrell Lowe, Noemi Balint, Maria Gimenez, Filipe Costa, Martina Labaiova, Dimeji Akinkuolie, Will Ingham
Lead Designer | John Hammond 

Publisher | Susanne Hauner
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Copyright 2021 NRi Digital, a trading division of Verdict Media Ltd. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | Time for UK plasma to shineGo to article: In this issueGo to article: ContentsGo to article: DatwylerGo to article: LabcorpGo to article: UPS Healthcare Company InsightGo to article: UPS Healthcare Go to article: BaxterGo to article: SHL MedicalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: PerkinElmerGo to article: CommentGo to article: A new day for Alzheimer’s disease treatmentGo to article: Covid-19 vaccine inequity: the debate over patent waivers intensifiesGo to article: Covid-19 vaccines show efficacy in adolescentsGo to article: International pharmacovigilance for biotechs: forming a strategyGo to article: NiproGo to article: HOF SonderanlagenbauGo to article: MyonexGo to article: In DepthGo to article: Malaria vaccines through the agesGo to article: Are competition authorities tightening the rules on pharma M&A? Go to article: The fishy business of shark squaleneGo to article: Without a trace: can pharma reduce scarring?Go to article: Blood plasma production: OK for the UK?Go to article: When the drugs don’t work: can pharma keep up with mental health?Go to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue